Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 471-478

  Van der Wilt, C L ^a   Smid, K ^a   Aherne, G W ^b   Noordhuis, P ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

5 fluorouracil; colon cancer; interferons

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; FLUOROURACIL; GAMMA INTERFERON; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG INTERACTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0031105022     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89024-7     Document Type: Article

References (46)

1. Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 48:1988;4868-4873.
2. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 50:1990;5834-5840.
3. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase-II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma - an Eastern Cooperative Oncology Group study. J Clin Oncol. 9:1991;1806-1810.
4. Grem JL, Jordan D, Robson ME, et al. Phase II study of fluorouracil leucovorin and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol. 11:1993;1737-1745.
5. Wadler S, Schwartz EL. Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytoxic chemotherapeutic drugs and interferon. Cancer Chemother Pharmacol. 35:1994;21-30.
6. Kocha W. Phase III randomized study of two fluorouracil combinations with either IFN alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group J Clin Oncol. 13:1995;921-928.
7. Hill M, Norman A, Cunningham D, et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal carcinoma. J Clin Oncol. 13:1995;1297-1302.
8. Hill M, Norman A, Cunningham D, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol. 13:1995;2317-2333.
9. Toth CA, Thomas P. Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo. Br J Cancer. 65:1992;365-368.
10. Lockshin A, Danenberg PV. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthase. Biochem Pharmacol. 30:1981;247-257.
11. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun. 163:1989;867-874.
12. Schwartz E, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cell lines. Biochem Biophys Res Commun. 3:1992;1232-1239.
13. Houghton JA, Adkins DA, Rahman A, Houghton PJ. Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-α2a in cultured colon adenocarcinoma cells. Cancer Commun. 3:1991;225-231.
14. Sinnige HAM, Timmer-Boscha H, Peters GJ, De Vries EGE, Mulder NH. Combined modulation by leucovorin and α-2a interferon of fluoropyrimidine mediated growth inhibition. Anticancer Res. 13:1993;1335-1340.
15. Houghton JA, Morton CL, Atkins DA, Rahman A. Locus of the interaction among 5-fluorouracil, leucovorin and interferon-α-2a in colon carcinoma cells. Cancer Res. 53:1993;4243-4250.
16. Milano G, Fischel JL, Etienne MC, et al. Inhibition of dihydropyrimidine dehydrogenase by α-interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol. 34:1994;147-152.
17. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxyfluorouridine. Jpn J Cancer Res. 84:1993;341-347.
18. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol. 32:1993;333-338.
19. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol. 43:1993;527-533.
20. Chu E, Koeller DM, Casey JL, et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA. 88:1991;8977-8981.
21. Klohs WD, Steinkampf RW. Possible link between intrinsic drug resistance of colon tumors an a detoxification mechanism of intestinal cells. Cancer Res. 48:1988;3025-3030.
22. Peters GJ, Kraal I, Pinedo HM. In vitro and in vivo studies on the combination of brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine. Br J Cancer. 65:1992;229-234.
23. Noguchi PR, Wallace J, Johnson EM, et al. Characterization of WIDR: a human colon carcinoma cell line. In Vitro. 15:1979;401-408.
24. Leibovitz A, Stinson JC, McCombs WB III, Cameron E, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36:1976;4562-4569.
25. Van der Wilt CL, Cloos J, De Jong M, Pinedo HM, Peters GJ. Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol Res. 7:1995;317-321.
26. Skehan P, Storeng R, Scudiero D, et al. New colorimetric assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;107-112.
27. Keepers YPAM, Pizao PE, Peters GJ, Van Ark-Otte J, Winograd B. Comparison of the sulphorhodamine B protein and tetrazolium (MMT) assays for in vitro chemosensitivity testing. Eur J Cancer. 27:1991;897-900.
28. Peters GJ, Wets M, Keepers YPAM, et al. Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer. 54:1993;450-455.
29. Van der Wilt CL, Visser GWM, Braakhuis BJM, et al. In vitro antitumor activity of cis- and trans-5,6-dihydro-6-alkoxy-uracils; effect on thymidylate synthesis. Br J Cancer. 68:1993;702-707.
30. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ. Elevation of thymidylate synthase after 5-fluorouracil in murine tumors is prevented by the addition of folinic acid. Cancer Res. 52:1992;4922-4928.
31. Van der Wilt CL, Braakhuis BJM, Pinedo HM, De Jong M, Smid K, Peters GJ. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int J Cancer. 61:1995;672-678.
32. Birnboim HC, Jevcak JJ. Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res. 41:1981;1889-1892.
33. Meijer C, Mulder NH, Timmer-Bosscha H, Zijlstra JG, De Vries EGE. Role of free radicals in adriamycin-resistant human small cell lung cancer cell line. Cancer Res. 47:1987;4613-4617.
34. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:1996;521-530.
35. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in vivo. Cancer Res. 50:1990;5212-5218.
36. Aherne GW, Hardcastle A, Newton R. Measurement of human thymidylate synthase (hTS) in cell lines using ELISA. Ann Oncol. 3:(Suppl. 1):1992;77.
37. Maas IWHM, Boven E, Pinedo HM, Schlüper HMM, Haisma HJ. The effects of gamma-interferon with 5-fluorouracil and 5-fluoro-2′-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J Cancer. 48:1991;749-756.
38. Fidler IJ, Fogler WE, Kleinerman ES, et al. Abrogation of species specificity for activation of tumordical properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. J Immunol. 135:1985;4289-4296.
39. Van der Wilt CL, Peters GJ. New targets for pyrimidine antimetabolites for the treatment of solid tumors: I. Thymidylate synthase. Pharmacy World & Sci. 16:1994;84-103.
40. Gewert DR, Shah S, Clemens MJ. Inhibition of cell division by interferons. Changes in the transport and intracellular metabolism of thymidine in human lymphoblastoid (Daudi) cells. Eur J Biochem. 116:1981;487-492.
41. Schwartz EL, Baptiste N, O'Connor CJ, Wadler S, Otter BA. Potentiation of antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res. 54:1994;1472-1478.
42. Tevaearai HT, Laurent PL, Suardet L, Eliason JF, Givel JC, Odarchenko N. Interactions of interferon-α2a with 5′-deoxy-5-fluorouridine in colorectal cancer cells in vitro. Eur J Cancer. 28:1992;368-372.
43. Johnston PG, Drake JC, Treperl J, Allegra CJ. Immunological quantification of thymidylate synthase using the monoclonal antibody TS106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 52:1992;4306-4312.
44. Pestalozzi BC, McGinn CJ, Kinsella TJ, et al. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer. 71:1995;1151-1157.
45. Tanaka M, Kimura K, Yoshida S. Inhibition of mammalial DNA polymerase by recombinant α-interferon. Cancer Res. 47:1987;107-112.
46. Wadler S, Horowitz R, Mao X, Schwartz EL. Effect of interferon on 5-fluorouracil induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Cancer Chemother Pharmacol. 38:1996;529-535.